Cross-Sector entity
MarketBeat is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. Across a 28-day span, the pace is roughly 5 stories per week. The busiest single day carried 4. The clearest coverage concentration is markets: 10 of 20 stories, with the rest divided among 8 other categories.
72 verified stories tracked
Last mentioned: 4d ago
Entity pulse
Coverage balance Balanced directional read. Positive and negative coverage are within 5 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
MarketBeat is most often covered alongside Weiss Ratings, which appears in 10 of these 20 stories. Across a 28-day span, the pace is roughly 5 stories per week. The busiest single day carried 4. The clearest coverage concentration is markets: 10 of 20 stories, with the rest divided among 8 other categories. 5% of these stories carry negative sentiment. This profile follows 20 Cross-Sector stories mentioning MarketBeat across the period from August 13, 2026 to September 9, 2026. The tracked stories average 2.1 original sources each.
Computed from the 20 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering MarketBeat. Shared-story counts are live from our verified record — not editorial picks.
Eaton Shares Rise 2.8%
Shares trade as high as $430.25 and last at $422.2780, closing above the 50-day and 200-day moving averages.
Morgan Stanley and Weiss Ratings Turn Constructive
Morgan Stanley raises its Eaton target to $520 from $500 and Weiss Ratings upgrades the stock from hold to buy.
Wall Street Zen issues opposing ratings
Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
Wall Street Zen Downgrades Eaton
Wall Street Zen lowers Eaton from buy to hold, diverging from the broader bullish consensus.
Benchmark cuts BKKT target
Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
T1 Energy earnings and BTIG target move
T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.
Bakkt reports quarterly results
Bakkt announced EPS of $1.94 and revenue of $170.15 million, missing revenue consensus of $373.27 million.
Truist raises SM Energy target
Increased price target from $37.00 to $43.00 and maintained a Buy rating.
Wall Street Zen cuts STAG and ZVIA to Sell
Wall Street Zen downgraded both Stag Industrial and Zevia PBC from hold to sell in weekend research notes.
Cantor Fitzgerald raises DEI target
Cantor Fitzgerald raised its Douglas Emmett target price from $12.00 to $13.00 with a neutral rating.
ZVIA reports Q2 results
Zevia PBC reported EPS of -$0.03, hitting consensus, and revenue of $45.00 million versus a $44.21 million estimate.
SM Energy quarterly results
SM Energy reported $2.19 earnings per share for the quarter.
Douglas Emmett reports earnings
Douglas Emmett reported quarterly EPS of negative $0.02.
Multiple Analyst Target Raises
RBC raises target to $512, BMO to $487, Citigroup to $485, and Sanford C. Bernstein reiterates outperform on Eaton.
Weiss reiterates buy on STAG; Baird sets $138 target
Weiss Ratings reiterated a buy (b-) rating on Stag Industrial, while Robert W. Baird set a $138.00 target price.
Eaton Reports Q2 Earnings
Eaton reports EPS of $3.15, surpassing consensus estimates of $3.08 by $0.07.
STAG reports Q2 earnings miss
Stag Industrial reported EPS of $0.28, missing the consensus estimate of $0.65 by $0.37; revenue was approximately $224 million.
Weiss Ratings upgrades DEI
Weiss Ratings upgraded Douglas Emmett from a sell (d) rating to a sell (d+) rating.
Scotiabank raises DEI target
Scotiabank raised its Douglas Emmett target price from $12.00 to $13.00 with a sector perform rating.
Two updates on SM Energy
Susquehanna lifted its SM target from $31 to $32 (Neutral); Raymond James lowered its target from $55 to $48 (Outperform).
Lucid Group shares fell 1.1% to $4.63 on September 8, 2026, trading 25% below its 50-day moving average of $6.17. With a consensus Reduce rating and a $9.22 price target, the stock's negative EPS and 3.0 debt-to-equity ratio pose significant downside risk for value and momentum investors.
Source: tickerreport.com · dailypolitical.com
Eaton's 2.8% climb to $422.28 reflects a cluster of price-target raises led by Morgan Stanley and RBC. For finance readers, the key tension is a 20-analyst Buy consensus versus a 42.96 P/E and 2.60 PEG that price in significant electrification growth.
Source: tickerreport.com · dailypolitical.com
Tuesday's midday tape lifted MARA 4.6% to $11.83 and Sterling Infrastructure 3.2% to $502.20, but the more important signal for investors is a multi-week pattern of analyst price-target cuts. MARA's consensus target of $18.78 implies large upside yet carries 5.32 beta and negative earnings; STRL's $690.33 target still sits 37% above its price but below prior $900-plus targets. Finance readers should weigh consensus 'Moderate Buy' labels against balance-sheet and technical risks.
Source: themarketsdaily.com · tickerreport.com
Needham & Company reiterated Buy ratings on Salesforce (CRM) and Solaris Energy Infrastructure (SEI) with price targets of $400 and $98. CRM opened at $259.39, implying 54% upside, while SEI opened at $55.08, implying 78% upside. The ratings highlight divergent risk-reward profiles across software and energy infrastructure.
Source: tickerreport.com · dailypolitical.com
Lululemon's Q3 guidance implies a 62% EPS gap to consensus and an 11.5% revenue shortfall, signaling accelerating weakness in premium athleisure demand. The reset comes even as shares rose 1.4% on heavy volume, suggesting bad news was largely priced in. Retailers and DTC brands should read this as a leading indicator of softening consumer demand for discretionary premium apparel.
Source: MarketBeat · tickerreport.com
A MarketBeat screener for August 23, 2026 ranks Taiwan Semiconductor, Applied Materials, and Fabrinet among the top-volume manufacturing names, signaling capital flows into semiconductor production capacity. Honeywell Aerospace and Phillips 66 round out the list, tying the signal to aerospace and energy supply chains.
A MarketBeat volume scan for August 23, 2026 flags 19 names across manufacturing, penny, and mid-cap categories, including semiconductor heavyweights, six crypto miners, two airlines, and a leveraged TSLA ETF. The mix points to broad speculative and cyclical positioning rather than a single sector theme.
Source: themarketsdaily.com · tickerreport.com
Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Source: themarketsdaily.com · dailypolitical.com
A dollar-volume screen put Palo Alto Networks, CrowdStrike, and Fortinet atop the cybersecurity group on August 21 — a liquidity snapshot showing investor conviction concentrating in scaled, AI-native security platforms. The same day, PANW and CRWD both traded higher, with CRWD's gen-AI workload security noted as a key differentiator.
Bitdeer, Core Scientific, and Figure led blockchain-stock dollar volume on August 21, with CORZ up 4.1% while BTDR slipped 1.2% as bitcoin held near $118,450. The screen highlights how mining equities trade as liquid, leveraged proxies for BTC.
Source: themarketsdaily.com · dailypolitical.com
MarketBeat's August 19 high-volume value screen names Moderna, QQQ, Intel, Nebius, and SpaceX, while a large-cap screen adds SanDisk and Micron. The list highlights where dollar volume concentrated, but classifications include an ETF and a private company, so investors should validate the data before acting.
Moderna appears on both MarketBeat's value and large-cap high-volume screens on August 19, underscoring unusual liquidity and renewed biotech interest despite a post-COVID valuation reset. The mRNA pipeline spans respiratory, latent, and public health vaccines, setting up multiple clinical catalysts.
Source: watchlistnews.com · tickerreport.com
Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Source: themarketsdaily.com · dailypolitical.com
Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Source: tickerreport.com · themarketsdaily.com
A head-to-head comparison of two small-cap tech names reveals a sharp risk divergence: Key Tronic's 1.19 beta and 40.7% institutional backing contrast with Schmitt Industries' rare negative -0.21 beta and 17.1% insider ownership. Investors must decide between a contract manufacturer with above-market volatility and a niche instrumentation play with inverse correlation to the S&P 500.
Source: dailypolitical.com · tickerreport.com
For healthcare and medical device stakeholders, Apyx Medical's Q1 revenue of $12.49 million beat consensus by $1.96 million, yet the stock fell 1.8% to $4.38. The decline on 60% below-average volume suggests limited conviction, while analysts maintain a moderate buy rating and $6.50 target. The company's strong liquidity ratios contrast with its negative net margin and return on equity.
For biotech and pharma investors, Apyx Medical's Q1 loss of $0.05 per share beat consensus by $0.06, but the stock fell 1.8% to $4.38 on low volume. Mixed analyst ratings and a $6.50 consensus target raise questions about whether the small-cap device maker can convert clinical and operational beats into stock appreciation. Institutional repositioning signals ongoing evaluation of the company's commercial ramp.
Source: dailypolitical.com · tickerreport.com
MarketBeat's screener surfaced five blockchain equities with the highest dollar volume on July 25, 2026: Core Scientific, Bitdeer, Globant, Figure Technology Solutions, and Digi Power X. For crypto-native investors, these public names offer indirect exposure to mining, infrastructure, and blockchain services without directly holding BTC. The list underscores where liquidity is rotating among blockchain-linked stocks amid continued volatility.
Source: tickerreport.com · dailypolitical.com
